Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Liabilities and Shareholders Equity (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Liabilities and Shareholders Equity for 11 consecutive years, with $138.2 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 1.16% to $138.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $589.6 million through Dec 2025, down 39.93% year-over-year, with the annual reading at $138.2 million for FY2025, 1.16% down from the prior year.
  • Liabilities and Shareholders Equity hit $138.2 million in Q4 2025 for Seres Therapeutics, down from $143.5 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $406.4 million in Q2 2023 to a low of $138.2 million in Q4 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $277.7 million across 5 years, with a median of $308.8 million in 2021.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 176.35% in 2021 and later plummeted 61.01% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $354.9 million in 2021, then fell by 1.71% to $348.8 million in 2022, then grew by 2.81% to $358.6 million in 2023, then crashed by 61.01% to $139.8 million in 2024, then dropped by 1.16% to $138.2 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for MCRB at $138.2 million in Q4 2025, $143.5 million in Q3 2025, and $143.8 million in Q2 2025.